Everything below concerns evidence gap. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
=== Jaundice === Gilbert syndrome produces an elevated level of unconjugated bilirubin in the bloodstream, but normally has no consequences. Mild jaundice may appear under conditions of exertion, stress, fasting, and infections, but the condition is otherwise usually asymptomatic. Severe cases are seen by yellowing of the skin tone and yellowing of the conjunctiva in the eye. Gilbert syndrome has been reported to contribute to an accelerated onset of neonatal jaundice. The syndrome cannot cause severe indirect hyperbilirubinemia in neonates by itself, but it may have a summative effect on rising bilirubin when combined with other factors, for example in the presence of increased red blood cell destruction due to diseases such as G6PD deficiency. This situation can be especially dangerous if not quickly treated, as the high serum bilirubin can cause irreversible neurological disability in the form of kernicterus.
== Biography == Meldal received B.S. and PhD degrees in chemical engineering from Technical University of Denmark (DTU); his PhD work was supervised by Klaus Bock and focused on the synthetic chemistry of carbohydrates. From 1983 to 1988 he was a postdoctoral fellow in organic chemistry, first at the DTU, next at the MRC Laboratory of Molecular Biology at Cambridge University and then at the University of Copenhagen. In 1996 he was appointed assistant professor at DTU. Since 1998 he has led the synthesis group in the Department of Chemistry of the Carlsberg Laboratory. Meldal developed several technological techniques and instruments for peptide synthesis near the start of his career. He developed the multiple-column synthesis used in peptide and organic synthesis instruments, as well as for assembling large split-mix libraries. He first presented the cycloaddition of acetylenes and azides used in peptide and protein conjugations, in polymers and in material sciences. Meldal's group has then showed this reaction to be orthogonal to the majority of functional group chemistries. More recently Meldal has developed an optical encoding technique and has focused on the merger of organic chemistry and peptide chemistry on solid support. He has devised a range of novel methods for the generation of N-acyl iminium ions in which combinatorial libraries of these compounds are generated and screened for substances with activity toward G protein-coupled receptors in cell-based on-bead screening.
Desmetramadol (INNTooltip International Nonproprietary Name), also known as O-desmethyltramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Tramadol is demethylated by the liver enzyme CYP2D6 to desmetramadol in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 will tend to have reduced analgesic effects from tramadol. Because desmetramadol itself does not need to be metabolized to induce an analgesic effect, it can be used in individuals with CYP2D6 inactivating mutations. Desmetramadol is commonly encountered as a designer drug online in powder form or as an ingredient in pressed pills due to being unscheduled in many jurisdictions. Outside of its role as a metabolite, a chemical used in research, and as a recreational drug, desmetramadol has a very limited history of human usage and is not approved for medicinal use in any country as of 2025.
==== Tax deduction for energy efficient commercial buildings ==== The tax credit for energy efficient commercial buildings is no longer available for any property if the construction begins after June 30, 2026.
== Epidemiology == The incidence and prevalence of PMD are unknown, and no studies have yet investigated its prevalence or incidence. However, it is generally agreed that PMD is a very rare condition. Some uncertainty regarding the incidence of PMD may be attributed to its confusion with keratoconus. PMD is not linked to race or age, although most cases present early in life, between 20 and 40 years of age. While PMD is usually considered to affect men and women equally, some studies suggest that it may affect men more frequently. Several diseases have been observed in people with PMD. However, no causal relationships have been established between any of the associated diseases and the pathogenesis of PMD. Such diseases include: chronic open angle glaucoma, retinitis pigmentosa, retinal lattice degeneration, scleroderma, kerato-conjunctivitis, eczema, and hyperthyroidism.
Sources: en.wikipedia.org
==== Other exercise types ==== A 2021 meta-analysis found that meditative exercise programs (tai chi, yoga, qigong) were superior to other forms of exercise (aerobic, flexibility, resistance) in improving sleep quality. Other meta-analyses also found positive effects of tai chi for sleep, fibromyalgia symptoms, and pain, fatigue, depression and quality of life. These tai chi interventions frequently included 1-hour sessions practiced 1–3 times a week for 12 weeks. Meditative exercises, as a whole, may achieve desired outcomes through biological mechanisms such as antioxidation, anti-inflammation, reduction in sympathetic activity, and modulation of glucocorticoid receptor sensitivity. Several reviews and meta-analyses suggest that aquatic training can improve symptoms and wellness in people with fibromyalgia. It is recommended to practice aquatic therapy at least twice a week using a low to moderate intensity. However, aquatic therapy does not appear to be superior to other types of exercise. Combinations of different exercises, such as flexibility and aerobic training, may improve stiffness. However, the evidence is of low-quality. It is not clear if flexibility training alone, compared to aerobic training, is effective at reducing symptoms or has any adverse effects. According to a 2017 systematic review it is uncertain whether vibration training in combination with exercise may improve pain, fatigue, and stiffness.
=== Kinematic viscosity === In fluid dynamics, it is sometimes more appropriate to work in terms of kinematic viscosity (sometimes also called the momentum diffusivity), defined as the ratio of the dynamic viscosity (μ) over the density of the fluid (ρ). It is usually denoted by the Greek letter nu (ν):
Cohn (1993), assistant secretary for strategy, planning, analysis & risk of the United States Department of Homeland Security Amit Bose (1994), acting administrator of the Federal Railroad Administration Karthik Ramanathan (1994), acting assistant secretary of the treasury for financial markets Frank Scaturro (1994), lawyer, public advocate who spearheaded the restoration of Grant's Tomb; Republican candidate for New York's 4th congressional district Radhika Fox (1995), acting assistant administrator for water of the United States Environmental Protection Agency Beto O'Rourke (1995), U.S. congressman for Texas's 16th congressional district and candidate in the 2020 United States presidential election Rebekah Gee (1997), secretary of the Louisiana Department of Health, daughter of Ohio State University president E. Gordon Gee Jay Carson (1999), executive director of C40 Cities Climate Leadership Group; former press secretary for Hillary Clinton and Howard Dean's presidential campaigns John Ray Clemmons (1999), member of the Tennessee House of Representatives from the 55th district George Demos (1999), former U.S.
Continuous-wave lasers however are often preferred to pulsed lasers due to the latter's relatively low duty cycle since they can only produce photo ions during the brief later pulses, and the difficulty in reproducing results due to pulse-to-pulse jitters, laser beam drifting, and wavelength variations. Moderate laser powers, if high enough to affect the desired transition states, can be used since the non-resonant photoionization cross section is low which implies a negligible ionization efficiency of unwanted atoms. The influence of the laser matrix to be used for the sample can also be reduced by separating evaporation and ionization processes both in time and in space. Another factor that could affect the efficiency and selectivity of the ionization process is the presence of contaminants caused by surface or impact ionization. This can be reduced up to appreciable orders of magnitude by using mass analysis so that isotopic compositions of the desired element are determined. Most of the elements of the Periodic Table can be ionized by one of the several excitation schemes available. The suitable excitation scheme depends on certain factors including the level scheme of the element's atom, its ionization energy, required selectivity and sensitivity, likely interference, and the wavelengths and power levels of the available laser systems. Most excitation schemes vary in the last step, the ionization step. This is due to the low cross-section for non-resonant photo-ionization produced by the laser.
==== Agents, brokers, and commission merchants ==== These firms typically do not take title to goods. Instead, they earn a commission or fee for matching buyers and sellers, negotiating terms, or arranging logistics.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.